Dr. Richard Larivière is a professor in the Department of Medicine at Laval University, and a researcher within the Endocrinology and Nephrology axis of the CHU of Quebec Research Centre. He is also Director of Master’s and PhD programs in Clinical and Biomedical Sciences of the Faculty of Medicine at Laval University. Following his doctoral studies in Clinical Sciences (cardiovascular pharmacology) at the Université de Montréal, and postdoctoral studies in molecular endocrinology at McGill University, Dr. Larivière established himself as a professor-researcher in nephrology and hypertension at L’Hôtel-Dieu de Québec. He is an active member of the Amgen-Laval University Research Chair in Nephrology, a multidisciplinary group of fundamentalist and clinical researchers.
The main objective of Dr. Larivière’s research is to better define the mechanisms of arterial hypertension and remodeling of the blood vessel wall. More specifically, he studies the role of endothelial dysfunction, that is, factors derived from the vascular endothelium in the pathogenesis of arterial hypertension, vascular and renal damage in the case of chronic renal failure, and aging. Over the years, he has demonstrated that an imbalance in endothelial production of vasoconstrictor and vasodilator factors, as well as pro-inflammatory factors, contributes significantly to the increase of arterial pressure and rigidity by stimulating, among other things, hypertrophic remodeling and calcification of the blood vessel wall. He has also demonstrated that endothelial dysfunction can be modulated by various endocrine factors and pharmacological agents, including certain drugs. Dr. Larivière’s research uses a variety of experimental models and human tissue libraries.
10, rue McMahon
Canada G1R 2J6
Data not available
- Anderson, SarahInternsarah.firstname.lastname@example.org
- Vandal-Gélinas, GabrielleUndergraduate studentL'Hôtel-Dieu de Québec+1 418-525-4444, extension email@example.com@crchudequebec.ulaval.ca
10 Rue Mcmahon
Ville de Québec, QC
Canada G1R 3S1
Endothelin-1 levels and cardiovascular risk factors in renal transplant patientsJournal Article
Clin Biochem, 37 (12), 2004.
Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic ratsJournal Article
Nephrol Dial Transplant, 16 (4), 2001.
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic ratsJournal Article
J Hypertens, 19 (8), 2001.
Renal and vascular effects of chronic nitric oxide synthase inhibition: involvement of endothelin 1 and angiotensin IIJournal Article
Can J Physiol Pharmacol, 77 (1), 1999.
Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal massJournal Article
Kidney Blood Press Res, 20 (6), 1997.
- Rôle de la dysfonction endothéliale dans le remodelage et la calcification vasculaire en insuffisance rénale chronique, from 2016-04-01 to 2025-03-31
Recently finished projects
- Accelerated CKD-related vascular calcification: Role of thiazide-type, thiazide-like and loop diuretics, from 2020-10-01 to 2023-05-31
- Proline hydroxylase inhibitors: linking HIF-1 to arterial calcification, from 2019-07-01 to 2021-09-30